News Sentiment

GRCE sentiment intelligence

Grace Therapeutics, Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 41 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.38 Week of 19 Jun 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 34

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

+8.2% over one week, +8.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Grace Therapeutics (GRCE) Advances FDA Resubmission Efforts for GTx-104

Market Reaction

Price moving ahead of tone

59/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction 8.2% Price confirming higher
Trend fit Trend inactive 8.2% over four weeks
Fair value -25.7% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 5
Neutral 33
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 34
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 15
Market source 7
simplywall.st 3
marketscreener.com 2
GlobeNewswire 2
Simply Wall Street 2
GuruFocus 1
TradingKey 1

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 13
Balance sheet 3
Deals and strategy 2
Regulatory and legal 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 41
Stock Titan Direct company coverage

Grace Therapeutics (NASDAQ: GRCE) VP departs, enters 12‑month consulting agreement

Grace Therapeutics (NASDAQ: GRCE) announced that Carrie D’Andrea will cease her role as VP of Clinical Operations effective June 5, 2026, and will receive severance benefits. Concurrently, she has entered into a 12-month consulting agreement for $250 per hour, during which her st

Tone
Neutral 50/100
Event
Market update
Published
06 Jun 2026 08:09
Source
Stock Titan